{"count": 5, "results": [{"_id": "35330695", "pmid": 35330695, "pmcid": "PMC8938169", "title": "Evaluation of Metformin Hydrochloride Tailoring Bilosomes as an Effective Transdermal Nanocarrier", "journal": "Int J Nanomedicine", "authors": ["Salem HF", "Nafady MM", "Ali AA", "Khalil NM", "Elsisi AA"], "date": "2022-03-17T00:00:00Z", "doi": "10.2147/IJN.S345505", "meta_date_publication": "2022", "meta_volume": "17", "meta_issue": "", "meta_pages": "1185-1201", "score": 50271.152, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin hydrochloride@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin HCL@@@), a first-line drug treating @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@diabetes type II@@@, was known to cause severe @<m>DISEASE_Gastritis</m> @DISEASE_MESH:D005756 @@@gastritis@@@, so seeking a non-oral dosage form was the new trend. ", "citations": {"NLM": "Salem HF, Nafady MM, Ali AA, Khalil NM, Elsisi AA. Evaluation of Metformin Hydrochloride Tailoring Bilosomes as an Effective Transdermal Nanocarrier Int J Nanomedicine. 2022;17():1185-1201. PMID: 35330695", "BibTeX": "@article{35330695, title={Evaluation of Metformin Hydrochloride Tailoring Bilosomes as an Effective Transdermal Nanocarrier}, author={Salem HF and Nafady MM and Ali AA and Khalil NM and Elsisi AA}, journal={Int J Nanomedicine}, volume={17}, pages={1185-1201}}"}}, {"_id": "40180700", "pmid": 40180700, "title": "Metformin Inhibits the Development of Helicobacter pylori-Associated Gastritis by Regulating the ERK-MMP10-IL-1beta Axis.", "journal": "Cell Biochem Biophys", "authors": ["Zhu W", "Li Q", "Kang M"], "date": "2025-04-04T00:00:00Z", "doi": "10.1007/s12013-025-01739-w", "meta_date_publication": "2025 Apr 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50254.082, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Inhibits the Development of @SPECIES_210 @@@Helicobacter pylori@@@-Associated @<m>DISEASE_Gastritis</m> @DISEASE_MESH:D005756 @@@Gastritis@@@ by Regulating the @GENE_MAPK1 @GENE_5594 @@@ERK@@@-@GENE_MMP10 @GENE_4319 @@@MMP10@@@-@GENE_IL1B @GENE_3553 @@@IL-1beta@@@ Axis.", "citations": {"NLM": "Zhu W, Li Q, Kang M. Metformin Inhibits the Development of Helicobacter pylori-Associated Gastritis by Regulating the ERK-MMP10-IL-1beta Axis. Cell Biochem Biophys. 2025 Apr 4;():. PMID: 40180700", "BibTeX": "@article{40180700, title={Metformin Inhibits the Development of Helicobacter pylori-Associated Gastritis by Regulating the ERK-MMP10-IL-1beta Axis.}, author={Zhu W and Li Q and Kang M}, journal={Cell Biochem Biophys}}"}}, {"_id": "38480622", "pmid": 38480622, "title": "A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors.", "journal": "Cell Biochem Funct", "authors": ["Tasnim J", "Hashim NM", "Han HC"], "date": "2024-03-01T00:00:00Z", "doi": "10.1002/cbf.3967", "meta_date_publication": "2024 Mar", "meta_volume": "42", "meta_issue": "2", "meta_pages": "e3967", "score": 50247.973, "text_hl": "Proton pump inhibitors (PPIs) are often prescribed in combination with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ or DPP-4 inhibitors (@CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@, @CHEMICAL_saxagliptin @CHEMICAL_MESH:C502994 @@@saxagliptin@@@, @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@, and @CHEMICAL_alogliptin @CHEMICAL_MESH:C520853 @@@alogliptin@@@) or a combined dose of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and DPP-4 inhibitor to treat @<m>DISEASE_Gastritis</m> @DISEASE_MESH:D005756 @@@gastritis@@@ in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Tasnim J, Hashim NM, Han HC. A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors. Cell Biochem Funct. 2024 Mar;42(2):e3967. PMID: 38480622", "BibTeX": "@article{38480622, title={A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors.}, author={Tasnim J and Hashim NM and Han HC}, journal={Cell Biochem Funct}, volume={42}, number={2}, pages={e3967}}"}}, {"_id": "37378123", "pmid": 37378123, "pmcid": "PMC10292010", "title": "Gout in an Obese Patient with Nonalcoholic Steatohepatitis on a Thiazide Diuretic and Association Between Hyperuricemia and Nonalcoholic Steatohepatitis: A Case Report", "journal": "Cureus", "authors": ["Khan Z", "Gul A"], "date": "2023-05-18T00:00:00Z", "doi": "10.7759/cureus.39207", "meta_date_publication": "2023 May", "meta_volume": "15", "meta_issue": "5", "meta_pages": "e39207", "score": 50233.695, "text_hl": "He also had a known case of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@, @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, and @<m>DISEASE_Gastritis</m> @DISEASE_MESH:D005756 @@@gastritis@@@, for which he has been taking the thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitors, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@, @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@, and @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@. ", "citations": {"NLM": "Khan Z, Gul A. Gout in an Obese Patient with Nonalcoholic Steatohepatitis on a Thiazide Diuretic and Association Between Hyperuricemia and Nonalcoholic Steatohepatitis: A Case Report Cureus. 2023 May;15(5):e39207. PMID: 37378123", "BibTeX": "@article{37378123, title={Gout in an Obese Patient with Nonalcoholic Steatohepatitis on a Thiazide Diuretic and Association Between Hyperuricemia and Nonalcoholic Steatohepatitis: A Case Report}, author={Khan Z and Gul A}, journal={Cureus}, volume={15}, number={5}, pages={e39207}}"}}, {"_id": "26032654", "pmid": 26032654, "title": "Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.", "journal": "J Clin Pharm Ther", "authors": ["Huang Y", "Sun J", "Wang X", "Tao X", "Wang H", "Tan W"], "date": "2015-08-01T00:00:00Z", "doi": "10.1111/jcpt.12290", "meta_date_publication": "2015 Aug", "meta_volume": "40", "meta_issue": "4", "meta_pages": "461-5", "score": 50064.785, "text_hl": "Asymptomatic @<m>DISEASE_Gastritis</m> @DISEASE_MESH:D005756 @@@chronic gastritis@@@ decreases @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ tolerance in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@.", "citations": {"NLM": "Huang Y, Sun J, Wang X, Tao X, Wang H, Tan W. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes. J Clin Pharm Ther. 2015 Aug;40(4):461-5. PMID: 26032654", "BibTeX": "@article{26032654, title={Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.}, author={Huang Y and Sun J and Wang X and Tao X and Wang H and Tan W}, journal={J Clin Pharm Ther}, volume={40}, number={4}, pages={461-5}}"}}]}